PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lee, Sophia Boyoung ^a   Doberstein, Kai ^a   Baumgarten, Peter ^b   Wieland, Anja ^c   Ungerer, Christopher ^a   Bürger, Claudia ^a   Hardt, Katja ^a   Boehncke, Wolf Henning ^a   Pfeilschifter, Josef ^a   Mihic Probst, Daniela ^d   Mittelbronn, Michel ^b   Gutwein, Paul ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; CISPLATIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PAX2; ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; MEMBRANE PROTEIN; PAX2 PROTEIN, HUMAN; SECRETASE;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CELL LEVEL; CELL MIGRATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; GENE SILENCING; GENETICS; METABOLISM; NEVUS; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MELANOCYTES; MELANOMA; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEVUS; PAX2 TRANSCRIPTION FACTOR; RNA, SMALL INTERFERING; SKIN NEOPLASMS;

EID: 80051857709     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022312     Document Type: Article

References (32)

1. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, et al. (2000) The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88: 2398-2424.
2. Kubic JD, Young KP, Plummer RS, Ludvik AE, Lang D, (2008) Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res 21: 627-645.
3. Dahl E, Koseki H, Balling R, (1997) Pax genes and organogenesis. Bioessays 19: 755-765.
4. Robson EJ, He SJ, Eccles MR, (2006) A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6: 52-62.
5. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, et al. (2001) The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 61: 4666-4670.
6. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, et al. (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289: 1357-1360.
7. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, et al. (2005) Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23: 8057-8064.
8. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, et al. (2004) Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22: 2671-2680.
9. He SJ, Stevens G, Braithwaite AW, Eccles MR, (2005) Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther 4: 996-1003.
10. Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, et al. (2001) PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61: 823-826.
11. Torban E, Eccles MR, Favor J, Goodyer PR, (2000) PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 157: 833-842.
12. Dressler GR, Douglass EC, (1992) Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci U S A 89: 1179-1183.
13. Gnarra JR, Dressler GR, (1995) Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 55: 4092-4098.
14. Silberstein GB, Dressler GR, Van Horn K, (2002) Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 21: 1009-1016.
15. Buttiglieri S, Deregibus MC, Bravo S, Cassoni P, Chiarle R, et al. (2004) Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem 279: 4136-4143.
16. Epstein J, Cai J, Glaser T, Jepeal L, Maas R, (1994) Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. J Biol Chem 269: 8355-8361.
17. Lee SB, Schramme A, Doberstein K, Dummer R, Abdel-Bakky MS, et al. (2010) ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 130: 763-773.
18. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, et al. (2009) Main roads to melanoma. J Transl Med 7: 86.
19. La Porta CA, (2009) Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets 9: 391-397.
20. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA, (2007) PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 73: 1-14.
21. Medic S, Ziman M, (2009) PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol 44: 85-97.
22. Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML, (2009) ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 15: 2288-2299.
23. Mochizuki S, Okada Y, (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98: 621-628.
24. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A, (2008) L1-CAM in cancerous tissues. Expert Opin Biol Ther 8: 1749-1757.
25. Hewitt SM, Hamada S, Monarres A, Kottical LV, Saunders GF, et al. (1997) Transcriptional activation of the bcl-2 apoptosis suppressor gene by the paired box transcription factor PAX8. Anticancer Res 17: 3211-3215.
26. Luu VD, Boysen G, Struckmann K, Casagrande S, von Teichman A, et al. (2009) Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 15: 3297-3304.
27. Wang Z, Sun Y, (2010) Targeting p53 for Novel Anticancer Therapy. Transl Oncol 3: 1-12.
28. Stuart ET, Haffner R, Oren M, Gruss P, (1995) Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14: 5638-5645.
29. Kaufmann R, Greiner D, Kippenberger S, Bernd A, (1998) Grafting of in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. Acta Derm Venereol 78: 136-138.
30. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
31. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, et al. (2001) Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643.
32. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, et al. (2001) Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155: 661-673.